BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year.
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.
These stocks are gapping in today's session The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.
7 Small-Cap Stocks to Buy for Large-Scale Gains Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic initiatives, BioCryst projects robust revenue
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024 BCRX stock results show that BioCryst Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects These penny stocks offer triple digit returns to investors right now but not many investors are aware of them.
